EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access

Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade

Mykhaylo Usyk, Richard B Hayes, Rob Knight, Antonio Gonzalez, Huilin Li, Iman Osman, Jeffrey S Weber, Jiyoung Ahn

Cell · 2026-06 · 189 (13) · 3940-3949.e14

DOI: 10.1016/j.cell.2026.03.041 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cell, 2026-06. Verfasst von Mykhaylo Usyk und 7 weiteren Autor:innen. Beteiligte Einrichtung: NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA;…. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Gastrointestinal Microbiome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with resected, high-risk melanoma receive adjuvant immune checkpoint blockade (ICB), yet clinical benefit remains unpredictable, with 25%-40% of patients experiencing recurrence. To evaluate whether pre-treatment gut microbiome (GMB) features predict recurrence, we analyzed stool samples from 674 patients enrolled in a phase 3 clinical trial, CheckMate 915, which investigated the combination of nivolumab plus ipilimumab versus nivolumab as a single agent across five geographic regions. Region-specific and cross-region meta-analyses identified pre-treatment taxa associated with recurrence, including Eubacterium, Ruminococcus, Firmicutes, and Clostridium. Recurrence prediction was strongest when the validation cohort exhibited GMB profiles similar to those in the discovery cohort. Among closely matched individuals (Jensen-Shannon divergence [JSD] ≤ 0.11), the area under the curve (AUC) for recurrence prediction ranged from 0.78 to 0.94 across regions. GMB composition remained largely stable following treatment. These findings suggest that gut bacterial markers can predict recurrence after adjuvant ICB treatment in melanoma, supporting their potential as clinically actionable biomarkers to guide personalized therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsGastrointestinal MicrobiomeHumansNeoplasm Recurrence, LocalIpilimumabDisease-Free SurvivalFemaleNivolumabMaleFecesMiddle AgedChemotherapy, Adjuvant

Stichwörter der Autor:innen

adjuvant therapybiomarkersclinical trialgeographic variationgut microbiomeimmune checkpoint blockadeipilimumabmelanomanivolumabrecurrence-free survival

Substanzen

Immune Checkpoint InhibitorsIpilimumabNivolumab

Autor:innen und Institutionen

  • NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA; Departments of Microbiology and Immunology, Albert Einstein College o…
  • NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Departments of Pediatrics, Computer Science & Engineering, and Bioengineering, Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA.
  • NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA; Department of Medicine, NYU Grossman School of Medic…
  • NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
  • NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA. Electronic address: jiyoung.ahn@nyulangone.org.

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIEHS NIH HHS
  • National Institutes of Health
  • National Library of Medicine
  • National Cancer Institute Division of Cancer Epidemiology and Genetics

Zitieren

APA

Usyk, M., Hayes, R. B., Knight, R., Gonzalez, A., Li, H., Osman, I., Weber, J. S., & Ahn, J. (2026). Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade. Cell, 189(13), 3940-3949.e14. https://doi.org/10.1016/j.cell.2026.03.041

Vancouver

Usyk M, Hayes RB, Knight R, Gonzalez A, Li H, Osman I, et al. Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade. Cell. 2026;189(13):3940-3949.e14. doi:10.1016/j.cell.2026.03.041

BibTeX
@article{Usyk2026,
  author = {Usyk, Mykhaylo and Hayes, Richard B and Knight, Rob and Gonzalez, Antonio and Li, Huilin and Osman, Iman and Weber, Jeffrey S and Ahn, Jiyoung},
  title = {Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {13},
  pages = {3940--3949.e14},
  doi = {10.1016/j.cell.2026.03.041}
}
Kostenlos starten →